| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Endocrinology, Vol 134, 1967-1970, Copyright © 1994 by Endocrine Society
ARTICLES |
MC Meriggiola, KD Dahl, JP Mather and WJ Bremner
Department of Veterans Affairs Medical Center, Seattle, WA.
Follistatin is an activin-binding glycoprotein that decreases FSH secretion in vitro and in vivo in rats. The mechanism by which follistatin acts is unclear, but it has been suggested that it may bind endogenous activin and neutralize its effects. In this study, we wished to test the ability of follistatin to suppress FSH secretion in vivo in primates whose FSH secretion has been stimulated by activin or by GnRH. Six prepubertal male monkeys were injected intravenously with human recombinant follistatin at the dose of 90 micrograms/kg or 180 micrograms/kg plus activin (90 micrograms/kg) or GnRH (10 micrograms/kg). Frequent blood samples were drawn for 12 hours following each injection. Bio FSH and LH levels were measured in those samples. GnRH and activin each stimulated FSH bioactivity. Both doses of follistatin significantly inhibited the activin-induced increase in FSH (p < 0.05). The GnRH-induced increase in FSH was not affected by follistatin. LH levels were not affected by follistatin in any of the studies. These data suggest that follistatin can suppress the activin- induced increase in FSH in primates and is consistent with the hypothesis that follistatin can block the physiological effects of endogenous activin in primates. This effect is likely to be due to the binding of follistatin to activin either in the peripheral circulation or at the pituitary level.
This article has been cited by other articles:
![]() |
H. T. Keutmann, A. L. Schneyer, and Y. Sidis The Role of Follistatin Domains in Follistatin Biological Action Mol. Endocrinol., January 1, 2004; 18(1): 228 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. O. Leal, K. Takabe, L. Wang, C. J. Donaldson, L. A. MacConell, L. M. Bilezikjian, I. M. Verma, and W. Vale Effect of Adenovirus-Mediated Overexpression of Follistatin and Extracellular Domain of Activin Receptor Type II on Gonadotropin Secretion in Vitro and in Vivo Endocrinology, March 1, 2002; 143(3): 964 - 969. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. V. Tortoriello, Y. Sidis, D. A. Holtzman, W. E. Holmes, and A. L. Schneyer Human Follistatin-Related Protein: A Structural Homologue of Follistatin with Nuclear Localization Endocrinology, August 1, 2001; 142(8): 3426 - 3434. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schwartz Intercellular Communication in the Anterior Pituitary Endocr. Rev., October 1, 2000; 21(5): 488 - 513. [Abstract] [Full Text] |
||||
![]() |
K. Ogawa, M. Funaba, L. S. Mathews, and T. Mizutani Activin A Stimulates Type IV Collagenase (Matrix Metalloproteinase-2) Production in Mouse Peritoneal Macrophages J. Immunol., September 15, 2000; 165(6): 2997 - 3003. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Veldhuis, A. Iranmanesh, L. M. Demers, and T. Mulligan Joint Basal and Pulsatile Hypersecretory Mechanisms Drive the Monotropic Follicle-Stimulating Hormone (FSH) Elevation in Healthy Older Men: Concurrent Preservation of the Orderliness of the FSH Release Process: A General Clinical Research Center Study J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3506 - 3514. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sidis, A. L. Schneyer, P. M. Sluss, L. N. Johnson, and H. T. Keutmann Follistatin: Essential Role for the N-terminal Domain in Activin Binding and Neutralization J. Biol. Chem., May 18, 2001; 276(21): 17718 - 17726. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |